New diabetes drug enters Head-to-Head test against leading treatment
NCT ID NCT07187856
Summary
This study aims to see if a new injectable drug, PG-102, can help control blood sugar and body weight in people with type 2 diabetes. It will compare PG-102 against a placebo (inactive shot) and an approved drug, semaglutide, over 24 weeks. The goal is to gather evidence on how well PG-102 works and how safe it is for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emeritus Research
Camberwell, Victoria, 3124, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.